Oncology Nurse Advisor22h
Imlunestrant Bests Standard Care in Certain Patients With ER+, HER2- Breast Cancer
The researchers found that imlunestrant prolonged progression-free survival (PFS) when compared to standard care in patients with ESR1 mutations, but there was no PFS benefit observed in the overall ...
Mum shares photo of lump bulging from breast after doctors repeatedly dismissed it – now she’s battling killer cancer
A MUM has shared a shocking photo of a giant lump protruding from her breast, which doctors repeatedly dismissed a benign.
FDA approves Datroway for HR-positive, HER2-negative breast cancer
The U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with ...
The American Journal of Managed Care15h
FDA Approves First HER2-Ultralow Companion Diagnostic, Expanding Treatment Eligibility
Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...
Roche Gets FDA Approval for Breast Cancer Test
The Swiss pharmaceutical company said the FDA backed a label expansion for the Pathway HER2 (4B5) test to identify patients with HR-positive, HER2-ultralow metastatic breast cancer who could be ...